Comparing Human Albumin Versus Hydroxyethylstarch in Renal Transplant Recipients

Not Applicable

Completed

• Conditions: Anesthesia Morbidity
• Interventions: Other: Albumin resuscitation; Other: Hydroxyethylstarch resuscitation; Drug: Albumin 5%; Drug: Hydroxyethylstarch 6%

• Registration Number: NCT03306914
• Lead Sponsor: Cairo University

Brief Summary

In this study we try to review the possible effects when using modern hydroxyethylstarch solutions 6 % versus albumin 5% during living donor renal transplantation.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-10-06
• Study First Submitted QC: 2017-10-06
• Study First Posted: 2017-10-11
• Study Start: 2017-10-15
• Primary Completion: 2019-02-01
• Study Completion: 2019-02-01
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-27
• Last Update Posted: 2020-01-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• end stage renal disease, for living donor renal transplantation

Read More

Exclusion Criteria

• severe cardiac or hepatic dysfunction, re-transplantation, coagulopathy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Albumin group	Albumin resuscitation	Albumin resuscitation Albumin 5%
Albumin group	Albumin 5%	Albumin resuscitation Albumin 5%
Hydroxyethylstarch group	Hydroxyethylstarch resuscitation	Hydroxyethylstarch resuscitation Hydroxyethylstarch 6%
Hydroxyethylstarch group	Hydroxyethylstarch 6%	Hydroxyethylstarch resuscitation Hydroxyethylstarch 6%

Primary Outcome Measures

Name	Time	Method
Occurrence of complications	7 days	Increased creatinine and/or need for dialysis

Trial Locations

Locations (1)

Cairo University; 🇪🇬 Cairo, Egypt